Contineum Therapeutics, Inc. (CTNM) — SEC Filings
Contineum Therapeutics, Inc. (CTNM) — 27 SEC filings. Latest: ARS (Apr 30, 2026). Includes 12 8-K, 6 10-Q, 4 SC 13G.
View Contineum Therapeutics, Inc. on SEC EDGAR
Overview
Contineum Therapeutics, Inc. (CTNM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 30, 2026: Contineum Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The filing includes a PDF document of the report and a complete submission text file. Contineum Therapeutics is a pharmaceutical company based in San Diego, Cali
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 1 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Contineum Therapeutics, Inc. is neutral.
Filing Type Overview
Contineum Therapeutics, Inc. (CTNM) has filed 1 ARS, 12 8-K, 6 10-Q, 1 DEF 14A, 1 10-K, 4 SC 13G, 1 S-1/A, 1 S-1 with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of CTNM's 22 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$12.8M |
| EPS | N/A |
| Debt-to-Equity | 0.06 |
| Cash Position | $182.4M |
| Operating Margin | N/A |
| Total Assets | $190.8M |
| Total Debt | $10.4M |
Key Executives
- Dr. Jonathan Leaman
- Dr. David Epstein
- Ms. Sarah Kelly
- Dr. Michael Stebel
- Carmine Stengone
- Peter Slover
- Daniel Lorrain, Ph.D.
- Stephen Huhn, M.D.
- Jonathan Leipsic
- David E. Cohen
- Sarah E. Kelly
- David M. R. Johnson
- Dr. Jonathan Leipsic
- Dr. David E. Johnson
- Dr. David M. Epstein
Industry Context
Contineum Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on neuroscience, inflammation, and immunology. This space is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include the increasing demand for novel therapies for complex diseases and the ongoing consolidation within the industry as companies seek to expand their pipelines and market reach.
Top Tags
financials (6) · 8-K (4) · 10-Q (4) · filing (3) · Biotechnology (3) · biotech (3) · management-change (3) · Contineum Therapeutics (3) · IPO (3) · disclosure (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-42001 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 27-1467257 | Company's tax identification number. |
| Net Loss (Q3 2025) | $12.8M | Increased from $10.3M in Q3 2024 |
| Net Loss (9 months ended Sep 30, 2025) | $44.8M | Increased from $27.7M in 9 months ended Sep 30, 2024 |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $38.8M | Increased from $25.4M in 9 months ended Sep 30, 2024 |
| Net Proceeds from ATM Offering | $19.0M | Raised during Q3 2025 by selling 3,241,110 shares |
| Cash, Cash Equivalents and Marketable Securities | $182.4M | As of September 30, 2025, expected to fund operations for at least 12 months |
| Accumulated Deficit | $162.2M | As of September 30, 2025, reflecting historical losses |
| Total Shares Outstanding | 29,182,511 | As of October 27, 2025 |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage. |
| Class A Common Stock Shares | 19,190,723 | outstanding as of June 30, 2025, representing ownership. |
| Class B Common Stock Shares | 6,729,172 | outstanding as of June 30, 2025, representing ownership. |
| Total Assets | $200.0B | As of March 31, 2025 |
| Total Liabilities | $19.1M | As of March 31, 2025 |
| Net Cash Used in Operations | $6.7M | For the three months ended March 31, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Contineum Therapeutics, Inc. (CTNM)?
Contineum Therapeutics, Inc. has 27 recent SEC filings from Mar 2024 to Apr 2026, including 12 8-K, 6 10-Q, 4 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CTNM filings?
Across 27 filings, the sentiment breakdown is: 1 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Contineum Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Contineum Therapeutics, Inc. (CTNM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Contineum Therapeutics, Inc.?
Key financial highlights from Contineum Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CTNM?
The investment thesis for CTNM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Contineum Therapeutics, Inc.?
Key executives identified across Contineum Therapeutics, Inc.'s filings include Dr. Jonathan Leaman, Dr. David Epstein, Ms. Sarah Kelly, Dr. Michael Stebel, Carmine Stengone and 11 others.
What are the main risk factors for Contineum Therapeutics, Inc. stock?
Of CTNM's 22 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Contineum Therapeutics, Inc.?
Forward guidance and predictions for Contineum Therapeutics, Inc. are extracted from SEC filings as they are enriched.